JMDC (4483) Q2 2025 earnings summary

Executive summary

• Revenue for H1 FY2024 rose 39.6% year-over-year to ¥19,197 million, driven by Healthcare-Big Data and Tele-medicine growth.

• EBITDA increased 39.9% to ¥4,619 million with a 24.1% margin; H1 results exceeded forecasts.

• Operating profit declined 9.8% to ¥3,250 million, but up 73% excluding subsidiary transfers.

• Net profit attributable to owners of parent fell 17.8% to ¥2,189 million, but up 59% excluding subsidiary transfers.

• H1 revenue and profit exceeded plan by 3% and 16% respectively.

Financial highlights

• Gross profit increased to ¥10,815 million from ¥7,575 million year-over-year.

• Total assets grew to ¥136,148 million, mainly due to higher cash and goodwill from acquisitions.

• Equity attributable to owners of parent rose to ¥72,075 million, with a ratio of 52.9%.

• Cash and cash equivalents at period-end were ¥27,456 million, up ¥12,982 million from March 31, 2024.

• Net cash provided by operating activities was ¥10,777 million; investing activities used ¥4,524 million; financing activities provided ¥6,729 million.

Outlook and guidance

• Full-year revenue forecast is ¥43,000 million, up 32.8% year-over-year; EBITDA projected at ¥12,000 million.

• Operating profit forecast is ¥9,300 million, up 32.7%; net profit forecast is ¥6,200 million, up 34.6%.

• Dividend forecast is unchanged at ¥14.00 per share for the fiscal year.

• No revision to full-year plan; progress ratios for revenue and profit are 35–45% of annual targets.